昭衍新药发预增，预计2025年度归母净利润同比增加约214%到371%

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of approximately RMB 233 million to RMB 349 million for the year 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1: Financial Performance - The increase in fair value is driven by a rise in market prices of biological assets and natural growth appreciation [1] - The laboratory operations have maintained a stable performance during the reporting period [1] Group 2: Revenue and Profitability - Due to the previous intense industry competition, the revenue and gross margin from performance contracts have decreased year-on-year [1] - The contribution of laboratory service business profits has declined [1]